Skip to main content
SpringerLink
Log in

Cost-effective options for advanced renal cell carcinoma

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Klijn S, et al. Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN190, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/87945?pdfid=58449

  2. Lakhdari K, et al. A Cost-Effectiveness Analysis of Nivolumab in Combination with Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN136, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85488?pdfid=58687

  3. Skentzou E, et al. Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma in the UK. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN94, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85429?pdfid=58691

  4. Kim S, et al. Cost-Effectiveness of Cabozantinib for Patients with Advanced Renal Cell Carcinoma after Failure of Prior Therapy in South Korea. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN144, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85389?pdfid=58689

  5. Mac Mullen M. Assessing the Budget Impact of Including Sunitinib for the Treatment of Metastatic Renal Cell Carcinoma in Argentina. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN70, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85506?pdfid=58681

  6. Derkach EV, et al. The Evaluation of the Economic Efficiency of Lenvatinib in Combination with Everolimus in Russian Patients with Disseminated Renal Cell Carcinoma. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN92, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/87927?pdfid=58454

  7. McDonald L, et al. Understanding Patient Perspectives of Renal Cell Carcinoma Using Social Media: a Qualitative Analysis. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN373, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/86456?pdfid=58612

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost-effective options for advanced renal cell carcinoma. PharmacoEcon Outcomes News 817, 13–14 (2018). https://doi.org/10.1007/s40274-018-5470-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5470-5

Search

Navigation